NYSE:OCX
OncoCyte Corp Stock News
$2.55
+0.0600 (+2.41%)
At Close: May 01, 2024
Chardan Capital Reaffirms Their Hold Rating on OncoCyte (OCX) - Markets
12:10pm, Tuesday, 30'th Jun 2020
In a report released today, Keay Nakae from Chardan Capital reiterated a Hold rating on OncoCyte (OCX – Research Report),
The following is a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 29) * ADC Therapeutics SA (NYSE: ADCT) * Altim
OncoCyte Corp (NYSEAMERICAN:OCX) to Post Q2 2020 Earnings of ($0.11) Per Share, Piper Sandler Forecasts
01:16am, Tuesday, 30'th Jun 2020
OncoCyte Corp (NYSEAMERICAN:OCX) – Piper Sandler issued their Q2 2020 earnings per share (EPS) estimates for OncoCyte in a research report issued to clients and investors on Wednesday, June 24th. Pi
The following is a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 29)
ADC Therapeutics SA (...
Oncocyte Announces Completion of DetermaDx™ Clinical Validation Study
08:05pm, Monday, 29'th Jun 2020
Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced th
OncoCyte (NYSEAMERICAN:OCX) Trading 3.3% Higher
06:15am, Wednesday, 24'th Jun 2020
OncoCyte Corp (NYSEAMERICAN:OCX)’s stock price was up 3.3% on Monday . The stock traded as high as $3.16 and last traded at $3.17, approximately 12,074 shares traded hands during trading. A decline
OncoCyte (NYSEAMERICAN:OCX) Downgraded to Sell at Zacks Investment Research
07:10am, Wednesday, 17'th Jun 2020
Zacks Investment Research lowered shares of OncoCyte (NYSEAMERICAN:OCX) from a hold rating to a sell rating in a report issued on Tuesday morning, Zacks.com reports. According to Zacks, “OncoCyte Co
Oncocyte Transitions to Revenue Generation as Multiple Payers Begin DetermaRx™ Reimbursements
12:00pm, Monday, 15'th Jun 2020
Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced it
Do Hedge Funds Love OncoCyte Corporation (OCX)?
08:18pm, Wednesday, 10'th Jun 2020
We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of Ma
OncoCyte (NYSEAMERICAN:OCX) Downgraded to Sell at Zacks Investment Research
05:24am, Wednesday, 10'th Jun 2020
OncoCyte (NYSEAMERICAN:OCX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Wednesday, Zacks.com reports. Accordin
Worldwide Bladder Cancer Market (2020 to 2024) - Develop In-depth Knowledge of Competition and Markets - ResearchAndMarkets.com
12:00am, Wednesday, 10'th Jun 2020
The
OncBioMune Announces Closing of Asset Purchase Agreement with Avant Diagnostics
02:16pm, Monday, 08'th Jun 2020
June 08, 2020 (ACCESSWIRE via COMTEX) --
Avant Diagnostics provides personalized medicine data for physicians and measures the activation state of key drug...
Global Precision Medicine Market Report 2020: Historic Analysis and Outlook 2015-2025 - ResearchAndMarkets.com
12:00am, Monday, 25'th May 2020
The
Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced pr
Edited Transcript of OCX earnings conference call or presentation 12-May-20 8:30pm GMT
07:18am, Wednesday, 13'th May 2020
Q1 2020 OncoCyte Corp Earnings Call
